Tasly Pharmaceutical Group Co., Ltd.

Tasly Biopharmaceuticals Co., Ltd.

Lihua Zhang

Xiaohui Ma

Jian Li

Yan Chen

Shunnan Zhang

Shuiping Zhou

Yibo Wang

Zhixin Guo

Xiaodan Cao

Genbei Wang

Lulu Yan

Sen Lin

Baoqing Fan

Ruijing Huang

Wenlei Li

Henry Sun

Pengyin Wang

The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3), or (HM-3)-Linker-Fc(IgG)-Linker-(HM-3). The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

HM-3 fusion protein and application thereof

The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.

Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof

Growing community of inventors

Tianjin, China

Lihua Zhang